An anti-inflammatory composition of Candida albicans which comprises heat-killed Candida albicans in combination with a neuroprotective supplement. The composition provides a method of stimulating a host immune response capable of reducing a total Candida albicans yeast load below the threshold necessary for the host to keep the Candida albicans yeast and related yeast species in a commensal, non-invasive state. This effect inhibits or prevents chronic inflammation related to invasive Candida genus and allows the composition to be useful for the prevention, prophylaxis, and/or treatment of chronic inflammatory conditions, as well as diseases and disorders of the central nervous system resulting from high L-glutamate levels due to Candida albicans in the gastrointestinal system.

A liquid capsule of cannabis, ginseng, and turmeric rhizome oil blend consisting essentially of an oil blend of cannabis oil, turmeric rhizome oil, and ginseng oil in a liquid capsule. There is less than 4 ppm of tetrahydrocannabinol (THC) in the oil blend.

The present invention relates to a melt composite comprising one or more curcuminoids and a carrier selected from rice bran extract, mannitol, maltodextrin and mixtures thereof. The invention also provides a process for preparation of the melt composite, wherein the mixture of curcuminoids, rice bran extract, mannitol, maltodextrin and mixture thereof may be subjected to controlled conditions of heating and granulation. The melt composite may also be optionally comprised of one more excipient suitable for use for human consumption. Curcuminoid composites can be formulated in suitable solid, liquid or semisolid compositions. Curcuminoid composites and the compositions thereof, exhibit rapid dissolution and enhanced bioavailability.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Mixed allergen compositions of one, two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chloropbenyl)(pbenyl)carbamoyloxy)methyl)cyclohexyi)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.

The present invention relates to a structure for the controlled release of at least one active substance, where the structure comprises the active substance and a cellular solid material comprising cellulose nanofibers (CNF). The structure has a density of less than 1000 kg/m3, and the cellular solid material comprises closed cells. The invention further relates to a method for preparing the structure; as well as the use of the structure.

The present application relates to compositions for the release of carbon dioxide following rectal administration comprising acid plant juices supported on gum and at least a salt of carbonic acid. Such compositions resulted to be particularly effective in stimulating evacuation, in particular showed an optimum kinetics of carbon dioxide release.

A composition for treatment of mucosal infection in an animal by application to a mucous membrane includes a mixture of IgY antibodies specific for a plurality of antigens obtained from a plurality of organisms, with the plurality of organisms able to cause infection of the mucous membrane. A protective matrix including non-hyperimmune colostrum can be combined with the mixture of IgY antibodies, with the protective matrix forming at least 20% by weight of the composition.